| | Roundtable: Creating Sustainable Change in HCP Engagement Tuesday, December 8 | 11am ET / 8am PT To succeed in today’s environment, biopharmaceutical companies must leverage analytics and adopt innovative approaches to engage HCPs and improve outcomes for their customers and communities. Join us for a roundtable discussion with leading industry innovators to discuss how biopharma manufacturers can successfully increase and improve HCP engagement. Register now. |
Moderna's COVID-19 vaccine aces phase 3, with no severe cases Rural hospitals struggle to find places to transfer patients amid COVID-19 surges J&J, erring on caution, tests new 2-dose regimen for COVID-19 vaccine Moderna's COVID vaccine is stable in refrigerators for 30 days, easing concerns around large-scale rollout CureVac, EU ink supply deal for up to 405M doses of mRNA coronavirus shot: Reuters Premier, 34 systems partner with global medical manufacturer to create domestic gown maker CommonSpirit Health posts $167M profit in Q3 as volumes remain down due to COVID-19 Biopharma roundup: CureVac, EU home in on 405M-dose vaccine deal; Pfizer, Moderna data no excuse for pandemic complacency, WHO warns Fierce Pharma Politics—Biden COVID task force plans meetings with vaccine makers Featured Story | By Nick Paul Taylor Moderna’s phase 3 COVID-19 vaccine has hit its primary endpoint with efficacy of 94.5%. Ninety cases of COVID-19, including all 11 severe cases seen so far, happened in the placebo cohort, versus five cases among people who received mRNA-1273. read more |
| |
|---|
|
Top Stories By Robert King Rural hospitals are struggling to find larger facilities to take care of patients that need more complex care as COVID-19 surges across the country. read more By Ben Adams Johnson & Johnson is confident that it has a one-dose knockout vaccine that can protect against COVID-19, but it’s now starting a late-stage two-dose test just in case. read more By Eric Sagonowsky A week after Pfizer posted impressive early coronavirus vaccine efficacy numbers, Moderna took the spotlight early Monday with impressive findings of its own. But separate from its big announcement, the mRNA biotech said its vaccine can be kept at refrigerated temperatures for 30 days, reducing hurdles for a potential large-scale rollout. read more By Eric Sagonowsky With mRNA-based coronavirus vaccines from Pfizer and Moderna showing promise in efficacy studies, another company working on a mid-stage mRNA candidate has inked a large supply deal with the European Union. CureVac, a German biotech, has agreed to supply the bloc with 225 million doses initially, with an option for another 180 million doses, Reuters reports. read more By Robert King Premier Inc. and 34 health systems have joined up with DeRoyal to create a new joint venture that will make isolation gowns in an effort to move personal protective equipment manufacturing to the U.S. read more By Robert King CommonSpirit Health has posted a $167 million profit in the latest quarter as the health system's patient volumes continue to rebound. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner The EU is in line for 405 million CureVac vaccine doses. Pfizer and Moderna's shot data shouldn't lead to pandemic complacency, WHO warned—though the drugmakers' shots could help control the pandemic in 2021, a former FDA commissioner said. Plus, some states are scrambling for ultra-cold freezers while others establish their own vaccine review panels. read more By Eric Sagonowsky As COVID-19 case counts reach previously unseen highs and vaccines show more promise than ever, the coronavirus team assembled by President-elect Joe Biden is planning to meet with vaccine developers this week. Still, the transition process is getting off to a rocky start. read more |
